Company Filing History:
Years Active: 2021-2025
Title: **The Innovations of Patrick Johnson in Complement-Mediated Disorders**
Introduction
Patrick Johnson is a notable inventor based in Zurich, Switzerland, recognized for his significant contributions to the field of biopharmaceuticals. With a robust portfolio of three patents, Johnson has been instrumental in advancing methods and compositions aimed at treating complement-mediated disorders.
Latest Patents
Johnson's recent work includes groundbreaking patents focusing on dosing regimens and related compositions. These patents detail cell-reactive compstatin analogs and compositions comprised of these analogs. Furthermore, Johnson has developed methods utilizing these compounds to inhibit complement-mediated damage to cells, tissues, or organs. His innovations also feature long-acting and targeted compstatin analogs, enhancing therapeutic applications for complement-mediated disorders.
Career Highlights
Patrick Johnson serves at Apellis Pharmaceuticals, Inc., where he leverages his expertise to drive research and innovation in the treatment of serious diseases linked to the immune system. His role allows him to explore new frontiers in biomedicine, particularly through the development of compstatin analogs that offer hope to patients suffering from complement-mediated conditions.
Collaborations
Johnson collaborates with esteemed colleagues, including Federico Grossi and Pascal Deschatelets, fostering a dynamic environment for innovation at Apellis Pharmaceuticals. Together, they work towards delivering advanced solutions and breakthroughs in therapeutic treatments.
Conclusion
With his expertise and dedication, Patrick Johnson exemplifies the spirit of innovation in the health sciences. His patents not only reflect his commitment to improving medical practices but also inspire future research in combating complement-mediated disorders, ultimately contributing to better patient outcomes.